0.05Open0.05Pre Close0 Volume218 Open Interest2.00Strike Price0.00Turnover157.79%IV49.64%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier20DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2057Delta0.5575Gamma27.40Leverage Ratio-0.0036Theta0.0001Rho5.63Eff Leverage0.0009Vega
Tempest Therapeutics Stock Discussion
Tempest Therapeutics, a clinical-stage biotechnology firm, recently announced a major milestone in their development of amezalpat (TPST-1120), a promising therapeutic agent for treating first-line unresec...
another good rating for a price target.
I wouldn't complain about 13.00 dollars
I want some of that 47 dollars share price target....lfg
No comment yet